Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc

Soluna Holdings ( ($SLNH) ) has issued an announcement. Soluna Holdings reported a significant financial performance for the third quarter of 2025,...

Soluna Holdings Secures $100M Credit Facility

Soleno Therapeutics ( ($SLNO) ) has issued an update. On November 11, 2025, Soleno Therapeutics announced that its Board of Directors approved an a...

Soleno Therapeutics Announces $100M Share Buyback Plan

Maxim Group analyst Tate Sullivan maintained a Buy rating on Stabilis Solutions yesterday. The company’s shares closed yesterday at $4.71. Sullivan...

Maxim Group Reaffirms Their Buy Rating on Stabilis Solutions (SLNG)

The latest update is out from Soluna Holdings ( ($SLNH) ). On November 6, 2025, Soluna Holdings announced significant updates in their operations, ...

Soluna Holdings Completes Phase 3 of Project Dorothy

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Soleno Therapeutics yesterday and set a price target of $123.00. Kluska covers ...

Cantor Fitzgerald Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Basilea Pharmaceutica today and set a price target of CHF105.00. The company’s sha...

H.C. Wainwright Keeps Their Buy Rating on Basilea Pharmaceutica (BSLN)

Basilea Pharmaceutica ( ($CH:BSLN) ) just unveiled an announcement. Basilea Pharmaceutica announced a USD 30 million sales milestone payment trigge...

Basilea Achieves Sales Milestone with Cresemba in Europe

Silence Therapeutics ( ($SLN) ) has provided an announcement. On October 23, 2025, Silence Therapeutics announced the completion of patient enrollm...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLN	$6.31	-0.63%	181.36K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLN	$6.31	-0.6%	181.36K
3
4
5
6

SLN

SLN

Get Silence Therapeutics Plc Data in Excel

Get Silence Therapeutics Plc Data in Excel